Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph(3,4OMe)

Cat. No.: HY-181078: Data Sheet Handling Instructions
FAQs
Technical Support

Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph (3,4OMe) is an anti-leukemic agent with potent ribosome-targeting protein synthesis inhibition. Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph (3,4OMe) downregulates short-lived oncoproteins, including c-Myc and Mcl-1, by inhibiting protein synthesis. Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph (3,4OMe) induces cell cycle arrest at the G0/G1 phase and triggers mitochondrial pathway-mediated apoptosis in acute myeloid leukemia (AML) cells. Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph (3,4OMe) is applicable for research on leukemia.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph(3,4OMe) 화학구조

사이즈		재고
MOQ		Minimum order quantity
50 mg		견적 받기
100 mg		견적 받기
250 mg		견적 받기
Other size		견적 받기

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

Biological Activity
순도&문서
References
고객리뷰

제품 설명

IC₅₀ & Target^[1]

Mcl-1

In Vitro

Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph(3,4OMe) (P2) (48 h) potently inhibits proliferation of U937, MOLM-13, NB4, Kasumi-1, Jurkat, K562, Raji, and JeKo-1 cells with sub-nanomolar to low nanomolar potency^[1].
Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph(3,4OMe) (1-3 nM; 24-72 h) suppresses proliferation of U937 and MOLM-13 cells in a dose- and time-dependent manner^[1].
Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph(3,4OMe) (1-3 nM; 24 h) induces G0/G1 phase cell cycle arrest in U937 and MOLM-13 cells in a concentration-dependent manner^[1].
Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph(3,4OMe) (48 h (Annexin V/PI staining); 24 h (JC-1 staining)) induces apoptosis in U937 and MOLM-13 cells via the mitochondrial pathway, and activation of caspase-9, caspase-3, and PARP cleavage^[1].
Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph(3,4OMe) (1 h (Western blot for protein turnover); 24 h (flow cytometry); 6 h (microscopy)) inhibits protein synthesis in U937, MOLM-13, and A375 cells, preferentially depleting short-lived oncoproteins (c-Myc, Mcl-1) while sparing long-lived proteins (HSP90)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	U937, MOLM-13
Concentration:	1 nM, 2 nM, 3 nM
Incubation Time:	24 h, 48 h, 72 h
Result:	Significantly suppressed proliferation of U937 and MOLM-13 cells in a dose- and time-dependent manner.

Apoptosis Analysis^[1]

Cell Line:	U937 and MOLM-13
Concentration:	1.25 nM, 2.5 nM, 5 nM (U937); 5 nM, 7.5 nM, 10 nM (MOLM-13)
Incubation Time:	48 h
Result:	Induced apoptosis in both U937 and MOLM-13 cells in a concentration-dependent manner.

Cell Cycle Analysis^[1]

Cell Line:	U937 and MOLM-13
Concentration:	1 nM, 2 nM, 3 nM
Incubation Time:	24 h
Result:	Induced significant concentration-dependent G0/G1 phase arrest in U937 and MOLM-13 cells.

Western Blot Analysis^[1]

Cell Line:	U937 and MOLM-13
Concentration:	1.25 nM, 2.5 nM, 5 nM (U937); 5 nM, 7.5 nM, 10 nM (MOLM-13)
Incubation Time:	48 h
Result:	Activated caspase-9 and caspase-3, and induced PARP cleavage, collectively confirming induction of the intrinsic mitochondrial apoptotic pathway.

분자량

613.72

화학식

C₃₂H₃₉NO₉S

SMILES

CCOC[C@@](CSC1=CC=C(C(OC)=C1)OC)(C(O[C@@H]2C(OC)=C[C@]34CCCN3CCC5=C([C@H]24)C=C6OCOC6=C5)=O)O

선적

Room temperature in continental US; may vary elsewhere.

보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Xu Z, et al. Discovery of novel and potent harringtonine derivative P2 via systematic structure-activity Optimization: Semi-Synthesis, anti-leukemia activity, and mechanism study. Eur J Med Chem. 2026;305:118546. [Content Brief]